Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CDX2
REST API REST API
Homo sapiens
CDX2 is differentially expressed in 185 experiments: 87 organism parts: prostate, kidney, ... (85 more);, 129 disease states: normal, colon carcinoma, ... (127 more);, 51 cell types 215 cell lines 19 compound treatments and 65 other conditions.
Synonyms CDX3
Orthologs F1N4C4_BOVIN (Bos taurus)   Cdx2 (Rattus norvegicus)   F6YJR3_CIOIN (Ciona intestinalis)   Cdx2 (Mus musculus)   cad (Drosophila melanogaster)   F1P2M4_CHICK (Gallus gallus)   cdx2 (Xenopus laevis)   CDX2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term pattern specification process, transcriptional repressor complex, condensed nuclear chromosome, protein binding, regulation of transcription, DNA-dependent, protein complex, transcription corepressor activity, transcription from RNA polymerase II promoter, cell differentiation, sequence-specific DNA binding, multicellular organismal development, nucleus, somatic stem cell maintenance, negative regulation of transcription from RNA polymerase II promoter, regulation of transcription from RNA polymerase II promoter, organ morphogenesis, labyrinthine layer development, placenta development, blood vessel development, positive regulation of cell differentiation, blastocyst development, trophectodermal cell differentiation, sequence-specific DNA binding transcription factor activity, anterior/posterior pattern specification
InterPro Term HTH_lambrepressr, Homeobox, Caudal_activation_dom, Homeobox_eu
UniProt Accession Q99626
Search EB-eye ENSG00000165556
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MTAB-25, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, E-GEOD-24147, E-GEOD-19480, ... (19 experiments)

Factor Value U/D Experiments
SW480
3
E-MTAB-37, E-MEXP-1014, E-GEOD-18005
AGS
1
2
E-MTAB-37, E-GEOD-15460
SNU16
2
E-MTAB-37, E-GEOD-15460
T84
2
E-MTAB-37, E-GEOD-1474
LU139
1
E-MTAB-62
J82
1
E-MTAB-37
209 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-13987, ... (29 experiments)

Factor Value U/D Experiments
memory B cell
2
E-MEXP-2360, E-TABM-702
promyelocyte
1
E-GEOD-12662
immortalized cell culture
1
E-GEOD-14990
CD34 positive
1
1
E-GEOD-12662
ovarian cancer
1
E-GEOD-21154
epidermal keratinocyte
1
E-GEOD-2822
45 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2466, E-GEOD-4045, E-GEOD-1869, ... (32 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-GEOD-96, E-MEXP-2034, E-MTAB-62
colon carcinoma
3
E-MTAB-37, E-GEOD-3726, E-MTAB-62
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
normal
4
5
E-GEOD-6338, E-GEOD-7307, E-GEOD-1145, E-MEXP-1121, E-MEXP-561, ... (9 experiments)
neuroblastoma
1
E-MTAB-62
123 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-412, E-GEOD-5824, E-MEXP-1335, ... (10 experiments)

Factor Value U/D Experiments
vanadium pentoxide
1
E-GEOD-5339
mercaptopurine, methotrexate
1
E-GEOD-412
4-hydroxytamoxifen
2
1
E-MEXP-2241
ethanol
1
E-MEXP-2241
Cxcl12
1
1
E-GEOD-7307
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
13 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-MEXP-1828, E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21374, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-MEXP-2359, E-MTAB-62 ... (5 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578

Genotype
studied in E-TABM-763, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, E-TABM-321, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1446, E-GEOD-22278, E-MEXP-1741

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-1648, E-TABM-15, ... (26 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-GEOD-980, E-GEOD-17400

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

pt
studied in E-GEOD-21653

RNAi
studied in E-MEXP-1509, E-MEXP-101

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89

Processing time: 0.465 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM